Perrigo Company (NYSE:PRGO) EVP Sharon Kochan sold 1,500 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $79.03, for a total value of $118,545.00. Following the transaction, the executive vice president now owns 10,349 shares of the company’s stock, valued at $817,881.47. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Perrigo Company (NYSE PRGO) traded down 1.08% during trading on Tuesday, hitting $78.06. The stock had a trading volume of 1,187,249 shares. The stock has a 50-day moving average of $75.12 and a 200 day moving average of $73.21. Perrigo Company has a 12-month low of $63.68 and a 12-month high of $99.14. The firm’s market cap is $11.13 billion.

Perrigo (NYSE:PRGO) last posted its earnings results on Thursday, August 10th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.28. Perrigo had a positive return on equity of 11.55% and a negative net margin of 51.04%. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the firm earned $1.93 earnings per share. The company’s revenue for the quarter was down 7.7% compared to the same quarter last year. On average, analysts predict that Perrigo Company will post $4.58 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Friday, August 25th will be paid a $0.16 dividend. The ex-dividend date is Wednesday, August 23rd. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.82%. Perrigo’s dividend payout ratio (DPR) is currently -3.51%.

ILLEGAL ACTIVITY WARNING: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://theolympiareport.com/2017/09/05/perrigo-company-prgo-evp-sells-118545-00-in-stock.html.

Several hedge funds have recently bought and sold shares of the company. BB&T Securities LLC grew its stake in shares of Perrigo by 0.4% in the second quarter. BB&T Securities LLC now owns 9,062 shares of the company’s stock valued at $684,000 after buying an additional 35 shares in the last quarter. Shufro Rose & Co. LLC grew its stake in shares of Perrigo by 1.2% in the second quarter. Shufro Rose & Co. LLC now owns 5,415 shares of the company’s stock valued at $409,000 after buying an additional 65 shares in the last quarter. Bank of Nova Scotia grew its stake in shares of Perrigo by 2.5% in the first quarter. Bank of Nova Scotia now owns 3,219 shares of the company’s stock valued at $214,000 after buying an additional 80 shares in the last quarter. Advantus Capital Management Inc grew its stake in shares of Perrigo by 0.6% in the first quarter. Advantus Capital Management Inc now owns 14,299 shares of the company’s stock valued at $949,000 after buying an additional 86 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Perrigo by 0.3% in the first quarter. Arizona State Retirement System now owns 35,500 shares of the company’s stock valued at $2,357,000 after buying an additional 100 shares in the last quarter. Institutional investors and hedge funds own 80.36% of the company’s stock.

A number of brokerages recently commented on PRGO. Stifel Nicolaus restated a “hold” rating on shares of Perrigo in a report on Friday, August 11th. Jefferies Group LLC restated a “hold” rating and set a $71.00 target price (up from $69.00) on shares of Perrigo in a report on Friday, August 11th. Wells Fargo & Company restated a “market perform” rating and set a $77.00 target price on shares of Perrigo in a report on Tuesday, August 15th. Cantor Fitzgerald restated a “buy” rating on shares of Perrigo in a report on Monday, August 21st. Finally, Goldman Sachs Group, Inc. (The) upgraded Perrigo from a “sell” rating to a “neutral” rating and raised their target price for the company from $66.00 to $79.00 in a report on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $86.83.

About Perrigo

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Insider Buying and Selling by Quarter for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with Analyst Ratings Network's FREE daily email newsletter.